OpenAI acquires Orchestra Bio in AI push for new drugs

What happened: OpenAI said it acquired platform startup Orchestra Bio to increase the use of artificial intelligence in developing new drug treatments. Terms of the deal were not disclosed. Key numbers: OpenAI is reportedly in talks to raise an additional $30B at a $1.4T valuation. Why it matters: OpenAI plans to combine its Rosalind AI models for life sciences with Orchestra's platform and team to build agents that help researchers connect findings with the studies and decisions needed to advance a potential medicine. Coverage: 3 outlets in 24h

OpenAI said it acquired platform startup Orchestra Bio to increase the use of artificial intelligence in developing new drug treatments. Terms of the deal were not disclosed.

OpenAI plans to combine its Rosalind AI models for life sciences with Orchestra's platform and team to build agents that help researchers connect findings with the studies and decisions needed to advance a potential medicine.